Surgical Decision Making and Management of CHEK2 and PALB2 Breast Cancer Mutation Carriers CHEK2 & PALB2 Carriers
Abstract
Background: Next-generation genetic sequencing has increasingly identified carriers of breast cancer susceptibility genes CHEK2 and PALB2. Despite the growing population of non-BRCA mutation carriers, literature on surgical decision-making in this cohort remains limited.
Methods: A retrospective cross-sectional study was conducted on patients diagnosed with CHEK2 or PALB2 genetic mutations between 2016 and 2024 at a breast clinic at a tertiary-care hospital. Demographics, surgical interventions, and complications were analyzed.
Results: Of over 4000 patients who were tested for a full breast cancer genetic panel, 132 CHEK2 and/or PALB2 positive patients were included. 74.2% had a personal history of breast cancer and 25.8% were tested as part of screening. Genetic diagnosis awareness significantly impacted surgical choices, with 36.7% of patients aware of their diagnosis choosing a mastectomy over breast-conserving therapy, compared to 15.7% of patients unaware of their diagnosis. There was a 23.0% conversion rate from BCT to mastectomy. 12 patients had autologous breast reconstruction and 28 had implant-based reconstruction. The major complication rate was 7.5%, and the minor complication rate was 12.5%.
Conclusion: Patients with CHEK2 or PALB2 genetic diagnoses have a lifetime breast cancer risk of up to 40%; high rates of cancer recurrence; and are six-times more likely to convert to a mastectomy after BCT compared to the general population. It is imperative that CHEK2/PALB2 carriers are informed about all surgical options—including contralateral prophylactic mastectomy, bilateral risk-reducing mastectomy, and breast reconstruction. Breast reconstruction is safe in this patient population, and early consultations are important for optimizing reconstructive outcomes.
Full text article
References
Centers for Disease Control and Prevention. Breast cancer: basic information. Updated January 17, 2024. Accessed July 24, 2024. https://www.cdc.gov/cancer/breast/basic_info/index.htm
Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–8
Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet. 2008;9:321–45.
Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134:326–330.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. Published 2024. Accessed July 1, 2024. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503
Meyer A, Dörk T, Sohn C, Karstens JH, Bremer M. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy. Radiother Oncol. 2007;82(3):349-353. doi:10.1016/j.radonc.2006.12.002
Breast Cancer Association Consortium, Mavaddat N, Dorling L, et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol. 2022;8(3):e216744. doi:10.1001/jamaoncol.2021.6744
Huszno J, Budryk M, Kołosza Z, et al. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis. Oncology. 2016;90(4):193-198. doi:10.1159/000444326
de Bock GH, Schutte M, Krol-Warmerdam EM, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet. 2004;41(10):731-735. doi:10.1136/jmg.2004.019737
West AH, Blazer KR, Stoll J, et al. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018;17(4):495-505. doi:10.1007/s10689-018-0070-x
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies [published correction appears in Am J Hum Genet. 2003 Sep;73(3):709]. Am J Hum Genet. 2003;72(5):1117-1130. doi:10.1086/375033
Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497-506. doi:10.1056/NEJMoa1400382
Frey JD, Salibian AA, Schnabel FR, Choi M, Karp NS. Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons. Plast Reconstr Surg Glob Open. 2017;5(11):e1564. Published 2017 Nov 20. doi:10.1097/GOX.0000000000001564
Yadav S, Boddicker NJ, Na J, et al. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023;41(9):1703-1713. doi:10.1200/JCO.22.01239
Tischkowitz M, Balmaña J, Foulkes WD, et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(8):1416-1423. doi:10.1038/s41436-021-01151-8
Committee on Publication Ethics. Committee on publication ethics (COPE): guidelines on good publication practice. Clin Oncol (R Coll Radiol). 2000;12(4):206-212. doi:10.1053/clon.2000.9154
Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-439. doi:10.1056/NEJMoa1913948
Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384(5):440-451. doi:10.1056/NEJMoa2005936
Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(17):1651-1652. doi:10.1056/NEJMc1410673
Lynch HT, Lynch J, Conway T, Severin M. Psychological aspects of monitoring high risk women for breast cancer. Cancer. 1994;74(3 Suppl):1184-1192. doi:10.1002/1097-0142(19940801)74:3+<1184::aid-cncr2820741530>3.0.co;2-4
Morrow M, Abrahamse P, Hofer TP, et al. Trends in Reoperation After Initial Lumpectomy for Breast Cancer: Addressing Overtreatment in Surgical Management. JAMA Oncol. 2017;3(10):1352-1357. doi:10.1001/jamaoncol.2017.0774
Ho AY, Hu ZI, Mehrara BJ, Wilkins EG. Radiotherapy in the setting of breast reconstruction: types, techniques, and timing. Lancet Oncol. 2017;18(12):e742-e753. doi:10.1016/S1470-2045(17)30617-4
Khansa I, Colakoglu S, Curtis MS, et al. Postmastectomy breast reconstruction after previous lumpectomy and radiation therapy: analysis of complications and satisfaction. Ann Plast Surg. 2011;66(5):444-451. doi:10.1097/SAP.0b013e3182166b81
Brackstone M, Baldassarre FG, Perera FE, et al. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39(27):3056-3082. doi:10.1200/JCO.21.00934
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.